Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS!!! The Coretec Group Completes Share Exchange Agreement with Core Optics
KEY HIGHLIGHTS:
*Completion of Share Exchange: The Coretec Group finalizes the acquisition of Core Optics, LLC, making it a wholly-owned subsidiary.
*Leadership Transition: Dr. Seonkee Kim was appointed as the new CEO of Core Optics.
*Strategic Expansion: Core Optics strengthens its position in the automotive camera module testing market, with over 90 patents and significant growth potential.
*Revenue Projections: Combined revenue forecast of $8M USD for fiscal year 2024 and $16M USD for fiscal year 2025.
*Market Opportunity: Positioned to capitalize on the global automotive camera market projected to grow to USD 18.18 billion by 2030.
ANN ARBOR, Mich., Aug. 22, 2024 (GLOBE NEWSWIRE) -- The Coretec Group (OTCQB: CRTG), a company focused on the development of silicon anode active materials for lithium-ion batteries and cyclohexasilane (CHS) for electric vehicles (EVs), cleantech, and emerging tech applications, today announced the successful completion of its share exchange agreement with Core Optics, LLC. This transaction, finalized on August 21, 2024, results in Core Optics becoming a wholly-owned subsidiary of The Coretec Group.
As part of the acquisition, Dr. Seonkee Kim has been appointed Chief Executive Officer of Core Optics. Core Optics is a leading manufacturer of testing and calibration equipment for Compact Camera Modules (CCM) used in automobiles, cell phones, and various other consumer and business technology applications. The company’s distinguished clientele includes Sony, Ford, Hyundai, Samsung, and other major blue-chip companies.[color=red][/color] With a 40,000 square foot facility in Korea and a dedicated team of over 40 employees, Core Optics has developed essential technologies and co-developed over 90 patents to safeguard its proprietary innovations. Core Optics is advancing the development of battery testing equipment, further driving the progress of The Coretec Group’s Endurion program.
The global automotive camera market is projected to grow from USD 8.81 billion in 2023 to USD 18.18 billion by 2030. Core Optics is strategically positioned to capitalize on this growth and has already established a strong foothold in the expanding industry.
The combined companies anticipate revenues of $8 million USD for fiscal year 2024 and $16 million USD for fiscal year 2025.
“We are experiencing high demand for our equipment, particularly in the automotive sector, and have plans in place to scale production to meet this growing demand,” said Dr. Kim, Chief Executive Officer of The Coretec Group. “The compact camera module market is seeing significant expansion, and our well-established product line positions us to increase revenue while also developing new products that will attract additional customers. Our presence in the U.S. opens doors to North American manufacturers and thriving capital markets, which we believe will elevate our corporate profile on a global scale.”
https://investors.thecoretecgroup.com/news/press-releases
NEWS!!! The Coretec Group Completes Share Exchange Agreement with Core Optics
KEY HIGHLIGHTS:
*Completion of Share Exchange: The Coretec Group finalizes the acquisition of Core Optics, LLC, making it a wholly-owned subsidiary.
*Leadership Transition: Dr. Seonkee Kim was appointed as the new CEO of Core Optics.
*Strategic Expansion: Core Optics strengthens its position in the automotive camera module testing market, with over 90 patents and significant growth potential.
*Revenue Projections: Combined revenue forecast of $8M USD for fiscal year 2024 and $16M USD for fiscal year 2025.
*Market Opportunity: Positioned to capitalize on the global automotive camera market projected to grow to USD 18.18 billion by 2030.
ANN ARBOR, Mich., Aug. 22, 2024 (GLOBE NEWSWIRE) -- The Coretec Group (OTCQB: CRTG), a company focused on the development of silicon anode active materials for lithium-ion batteries and cyclohexasilane (CHS) for electric vehicles (EVs), cleantech, and emerging tech applications, today announced the successful completion of its share exchange agreement with Core Optics, LLC. This transaction, finalized on August 21, 2024, results in Core Optics becoming a wholly-owned subsidiary of The Coretec Group.
As part of the acquisition, Dr. Seonkee Kim has been appointed Chief Executive Officer of Core Optics. Core Optics is a leading manufacturer of testing and calibration equipment for Compact Camera Modules (CCM) used in automobiles, cell phones, and various other consumer and business technology applications. The company’s distinguished clientele includes Sony, Ford, Hyundai, Samsung, and other major blue-chip companies.[color=red][/color] With a 40,000 square foot facility in Korea and a dedicated team of over 40 employees, Core Optics has developed essential technologies and co-developed over 90 patents to safeguard its proprietary innovations. Core Optics is advancing the development of battery testing equipment, further driving the progress of The Coretec Group’s Endurion program.
The global automotive camera market is projected to grow from USD 8.81 billion in 2023 to USD 18.18 billion by 2030. Core Optics is strategically positioned to capitalize on this growth and has already established a strong foothold in the expanding industry.
The combined companies anticipate revenues of $8 million USD for fiscal year 2024 and $16 million USD for fiscal year 2025.
“We are experiencing high demand for our equipment, particularly in the automotive sector, and have plans in place to scale production to meet this growing demand,” said Dr. Kim, Chief Executive Officer of The Coretec Group. “The compact camera module market is seeing significant expansion, and our well-established product line positions us to increase revenue while also developing new products that will attract additional customers. Our presence in the U.S. opens doors to North American manufacturers and thriving capital markets, which we believe will elevate our corporate profile on a global scale.”
https://investors.thecoretecgroup.com/news/press-releases
NEWS!!! The Coretec Group Completes Share Exchange Agreement with Core Optics
KEY HIGHLIGHTS:
*Completion of Share Exchange: The Coretec Group finalizes the acquisition of Core Optics, LLC, making it a wholly-owned subsidiary.
*Leadership Transition: Dr. Seonkee Kim was appointed as the new CEO of Core Optics.
*Strategic Expansion: Core Optics strengthens its position in the automotive camera module testing market, with over 90 patents and significant growth potential.
*Revenue Projections: Combined revenue forecast of $8M USD for fiscal year 2024 and $16M USD for fiscal year 2025.
*Market Opportunity: Positioned to capitalize on the global automotive camera market projected to grow to USD 18.18 billion by 2030.
ANN ARBOR, Mich., Aug. 22, 2024 (GLOBE NEWSWIRE) -- The Coretec Group (OTCQB: CRTG), a company focused on the development of silicon anode active materials for lithium-ion batteries and cyclohexasilane (CHS) for electric vehicles (EVs), cleantech, and emerging tech applications, today announced the successful completion of its share exchange agreement with Core Optics, LLC. This transaction, finalized on August 21, 2024, results in Core Optics becoming a wholly-owned subsidiary of The Coretec Group.
As part of the acquisition, Dr. Seonkee Kim has been appointed Chief Executive Officer of Core Optics. Core Optics is a leading manufacturer of testing and calibration equipment for Compact Camera Modules (CCM) used in automobiles, cell phones, and various other consumer and business technology applications. The company’s distinguished clientele includes Sony, Ford, Hyundai, Samsung, and other major blue-chip companies.[color=red][/color] With a 40,000 square foot facility in Korea and a dedicated team of over 40 employees, Core Optics has developed essential technologies and co-developed over 90 patents to safeguard its proprietary innovations. Core Optics is advancing the development of battery testing equipment, further driving the progress of The Coretec Group’s Endurion program.
The global automotive camera market is projected to grow from USD 8.81 billion in 2023 to USD 18.18 billion by 2030. Core Optics is strategically positioned to capitalize on this growth and has already established a strong foothold in the expanding industry.
The combined companies anticipate revenues of $8 million USD for fiscal year 2024 and $16 million USD for fiscal year 2025.
“We are experiencing high demand for our equipment, particularly in the automotive sector, and have plans in place to scale production to meet this growing demand,” said Dr. Kim, Chief Executive Officer of The Coretec Group. “The compact camera module market is seeing significant expansion, and our well-established product line positions us to increase revenue while also developing new products that will attract additional customers. Our presence in the U.S. opens doors to North American manufacturers and thriving capital markets, which we believe will elevate our corporate profile on a global scale.”
https://investors.thecoretecgroup.com/news/press-releases
Seems the transaction did not make to the cutoff date on the listing. Looking forward to the next update for clarification. Thanks
I get your point but if you look at the list, the top institutional holding is only 424,000 shares. The rest are miniscule amount. SIO Capital Management is a institutional investor and will show in the list if they are holding shares. Okay, to your point assuming its holdings is represented by another institution, even the top holder is only showing 424,000 shares as of June 2024 but I doubt that's SIO's. GL
https://stockzoa.com/ticker/nwbo/
Ooops... my bad. But not included in the list is indicative of not holding anymore shares as of June 30, 2024. No?
SIO is not on the list.
https://stockzoa.com/ticker/nwbo/
otcqb: ELTP alongside with the big boys Pfizer, Morgan Stanley Donaher...
"Elite Pharmaceuticals shares have outperformed the Zacks Medical – Drugs industry over the past two years (+302.3% vs. -16.8%). The Zacks analyst believes that the successful commercial launch of the company's Elite label product line, efficient cost management, robust product pipeline (including methotrexate), strategic partnerships, and financial prudence position it for sustained growth."
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
otcqb: ELTP alongside with the big boys Pfizer, Morgan Stanley Donaher...
"Elite Pharmaceuticals shares have outperformed the Zacks Medical – Drugs industry over the past two years (+302.3% vs. -16.8%). The Zacks analyst believes that the successful commercial launch of the company's Elite label product line, efficient cost management, robust product pipeline (including methotrexate), strategic partnerships, and financial prudence position it for sustained growth."
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
little gem ELTP alongside the big boys Pfizer, Morgan Stanley Donaher...
"Elite Pharmaceuticals' shares have outperformed the Zacks Medical – Drugs industry over the past two years (+302.3% vs. -16.8%). The Zacks analyst believes that the successful commercial launch of the company's Elite label product line, efficient cost management, robust product pipeline (including methotrexate), strategic partnerships, and financial prudence position it for sustained growth."
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
Zacks' Research Report on Pfizer,...
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
otcqb: ELTP alongside with the big boys Pfizer, Morgan Stanley Donaher...
"Elite Pharmaceuticals shares have outperformed the Zacks Medical – Drugs industry over the past two years (+302.3% vs. -16.8%). The Zacks analyst believes that the successful commercial launch of the company's Elite label product line, efficient cost management, robust product pipeline (including methotrexate), strategic partnerships, and financial prudence position it for sustained growth."
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
otcqb: ELTP alongside with the big boys Pfizer, Morgan Stanley Donaher...
"Elite Pharmaceuticals' shares have outperformed the Zacks Medical – Drugs industry over the past two years (+302.3% vs. -16.8%). The Zacks analyst believes that the successful commercial launch of the company's Elite label product line, efficient cost management, robust product pipeline (including methotrexate), strategic partnerships, and financial prudence position it for sustained growth."
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
otcqb: ELTP alongside with the big boys Pfizer, Morgan Stanley Donaher...
"Elite Pharmaceuticals' shares have outperformed the Zacks Medical – Drugs industry over the past two years (+302.3% vs. -16.8%). The Zacks analyst believes that the successful commercial launch of the company's Elite label product line, efficient cost management, robust product pipeline (including methotrexate), strategic partnerships, and financial prudence position it for sustained growth."
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
An otc coverage alongside with the big boys? The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer......
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
An otc listed among the big boys? The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer......
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer......
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
BioVie Day webinar is March 23, 2023 at 10:00 am ET
https://feeds.issuerdirect.com/news-release.html?newsid=8012584249565549
BioVie: Update On Alzheimer's And Parkinson's Programs, And Focus On Its Treatment For Refractory Ascites
https://seekingalpha.com/article/4587473-biovie-update-on-alzheimers-and-parkinsons-programs-and-focus-on-its-treatment-for-refractory-ascites
*****
Have you seen this?
Epalinges, Switzerland, March 24, 2022 - Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today a publication in Nature Scientific Reports in collaboration with the AMC – Amsterdam University Medical Center, with title: “A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike”.
https://www.mymetics.com/media-center/
2 consecutive scientific publication this year seems catches some attention on MYMX. Cheers!
regards,
Finally Published!
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
Funding
This work was supported by the Bill & Melinda Gates Foundation Grant OPP1111654 to RMR, NIH U19 AI142636 to RMR and SF, Collaboration for AIDS Vaccine Discovery, Vaccine Immune Monitoring Center (CAVIMC) grant OPP1146996, the National Institutes of Health/Office of Research Infrastructure Programs (NIH/ORIP) Grant P51 OD011133 to the Southwest National Primate Research Center (SNPRC) in San Antonio, TX, and National Institute of Allergy and Infectious Diseases (NIAID, Duke Center for AIDS Research (CFAR) grant P30 AI064518.
https://www.frontiersin.org/articles/10.3389/fimmu.2022.788619/full
>>> RMR - Ruth M. Rupretch, SF - Sylvain Fleury
regards,
Finally Published!
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
Funding
This work was supported by the Bill & Melinda Gates Foundation Grant OPP1111654 to RMR, NIH U19 AI142636 to RMR and SF, Collaboration for AIDS Vaccine Discovery, Vaccine Immune Monitoring Center (CAVIMC) grant OPP1146996, the National Institutes of Health/Office of Research Infrastructure Programs (NIH/ORIP) Grant P51 OD011133 to the Southwest National Primate Research Center (SNPRC) in San Antonio, TX, and National Institute of Allergy and Infectious Diseases (NIAID, Duke Center for AIDS Research (CFAR) grant P30 AI064518.
https://www.frontiersin.org/articles/10.3389/fimmu.2022.788619/full
regards,